Rapport Therapeutics, Inc. Common Stock
RAPP
Price:
$28.7
Market Cap:
$1.05B
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine recept...[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
RAPP
PE Ratio
[-12.64]
ROE
[-28.60%]
Current Ratio
[36.37]
Dividend Yield
[0%]
Enterprise Value
[807.99M]
Dividend History
The ROE as of December 2025 (TTM) for Rapport Therapeutics, Inc. Common Stock (RAPP) is -28.60%
According to Rapport Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current ROE is -28.60%. This represents a change of 276.73% compared to the average of -7.59% of the last 4 quarters.
Rapport Therapeutics, Inc. Common Stock (RAPP) Historical ROE (quarterly & annually)
How has RAPP ROE performed in the past?
The mean historical ROE of Rapport Therapeutics, Inc. Common Stock over the last ten years is -34.98%. The current -28.60% ROE has changed -18.23% with respect to the historical average. Over the past ten years (40 quarters), RAPP's ROE was at its highest in in the December 2023 quarter at 52.74%. The ROE was at its lowest in in the March 2024 quarter at -11.62%.
Average
-34.98%
Median
-25.64%
Minimum
-54.61%
Maximum
-24.68%
Rapport Therapeutics, Inc. Common Stock (RAPP) ROE by Quarter and Year
Discovering the peaks and valleys of Rapport Therapeutics, Inc. Common Stock ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.88%
Maximum Annual ROE = -24.68%
Minimum Annual Increase = -54.81%
Minimum Annual ROE = -54.61%
| Year | ROE | Change |
|---|---|---|
| 2024 | -25.64% | 3.88% |
| 2023 | -24.68% | -54.81% |
Rapport Therapeutics, Inc. Common Stock (RAPP) Average ROE
How has RAPP ROE performed in the past?
The current ROE of Rapport Therapeutics, Inc. Common Stock (RAPP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.98%
5-year avg
-34.98%
10-year avg
-34.98%
Rapport Therapeutics, Inc. Common Stock (RAPP) ROE vs. Peers
How is RAPP’s ROE compared to its peers?
Rapport Therapeutics, Inc. Common Stock’s ROE is greater than Nurix Therapeutics, Inc. (-53.57%), greater than Kodiak Sciences Inc. (-176.58%), less than Phathom Pharmaceuticals, Inc. (77.32%), greater than Xencor, Inc. (-26.73%), greater than BridgeBio Oncology Therapeutics Inc. (-77.14%), greater than AnaptysBio, Inc. (-1101.24%), greater than Mind Medicine (MindMed) Inc. (-86.18%), less than UroGen Pharma Ltd. (503.46%), greater than Oculis Holding AG (-90.60%), greater than Septerna, Inc. (-14.83%),
| Company | ROE | Market cap |
|---|---|---|
| -53.57% | $1.39B | |
| -176.58% | $1.31B | |
| 77.32% | $1.05B | |
| -26.73% | $1.30B | |
| -77.14% | $923.07M | |
| -1101.24% | $1.20B | |
| -86.18% | $939.13M | |
| 503.46% | $1.14B | |
| -90.60% | $1.03B | |
| -14.83% | $1.17B |
Build a custom stock screener for Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rapport Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Rapport Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Rapport Therapeutics, Inc. Common Stock's ROE?
How is the ROE calculated for Rapport Therapeutics, Inc. Common Stock (RAPP)?
What is the highest ROE for Rapport Therapeutics, Inc. Common Stock (RAPP)?
What is the 3-year average ROE for Rapport Therapeutics, Inc. Common Stock (RAPP)?
What is the 5-year average ROE for Rapport Therapeutics, Inc. Common Stock (RAPP)?
How does the current ROE for Rapport Therapeutics, Inc. Common Stock (RAPP) compare to its historical average?